Skip to ContentSkip to Navigation
How to find us C. Bisschop


Imaging and biomarkers to aid in treatment decisions in melanoma and rectal cancer

Rational use of 18F-FDG PET/CT in patients with advanced cutaneous melanoma: A systematic review

Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program

Rapid BRAF mutation tests in patients with advanced melanoma: Comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform

Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands

Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II Study

Vreemdlichaamreactie op fillers tijdens immunotherapie voor gemetastaseerd melanoom

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Foreign body reaction triggered by cytotoxic T lymphocyte-associated protein 4 blockade 25 years after dermal filler injection

Consequence of restaging after neoadjuvant treatment for locally advanced rectal cancer.

Read more